Charles River Laboratories International, Inc. (NYSE:CRL) has been assigned an average rating of “Buy” from the twelve research firms that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $99.55.

A number of equities research analysts recently commented on CRL shares. Jefferies Group LLC reiterated a “buy” rating and issued a $120.00 price objective on shares of Charles River Laboratories International in a report on Tuesday, September 12th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 target price for the company in a research note on Thursday, August 10th. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 target price for the company. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 22nd. Finally, Robert W. Baird reissued a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 1st.

In other news, Director George Massaro sold 3,830 shares of the company’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $100.81, for a total transaction of $386,102.30. Following the completion of the transaction, the director now directly owns 18,731 shares of the company’s stock, valued at $1,888,272.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the transaction, the insider now directly owns 11,671 shares of the company’s stock, valued at $783,124.10. The disclosure for this sale can be found here. Insiders have sold 22,529 shares of company stock valued at $2,278,496 over the last ninety days. 2.20% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Charles River Laboratories International by 0.5% during the second quarter. Vanguard Group Inc. now owns 5,060,730 shares of the medical research company’s stock worth $511,893,000 after buying an additional 27,217 shares during the period. BlackRock Inc. boosted its position in shares of Charles River Laboratories International by 4.6% during the second quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock worth $406,913,000 after buying an additional 177,239 shares during the period. FMR LLC boosted its position in shares of Charles River Laboratories International by 23.8% during the second quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock worth $311,458,000 after buying an additional 591,066 shares during the period. State Street Corp boosted its position in shares of Charles River Laboratories International by 2.3% during the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock worth $128,288,000 after buying an additional 28,365 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Charles River Laboratories International by 14.4% during the second quarter. Renaissance Technologies LLC now owns 1,219,883 shares of the medical research company’s stock worth $123,391,000 after buying an additional 153,374 shares during the period. 95.38% of the stock is owned by institutional investors.

WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/11/charles-river-laboratories-international-inc-crl-given-consensus-rating-of-buy-by-analysts.html.

Charles River Laboratories International (NYSE:CRL) traded up 0.62% during trading on Wednesday, hitting $112.49. The company had a trading volume of 17,513 shares. The firm has a 50-day moving average of $107.35 and a 200 day moving average of $97.74. Charles River Laboratories International has a 12-month low of $67.20 and a 12-month high of $112.83. The company has a market capitalization of $5.35 billion, a price-to-earnings ratio of 29.68 and a beta of 0.96.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.20 earnings per share. On average, equities research analysts forecast that Charles River Laboratories International will post $5.10 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.